Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Adams, Richard A.
Fisher, David J.
Graham, Janet
Seligmann, Jenny F.
Seymour, Matthew
Kaplan, Richard
Yates, Emma
Parmar, Mahesh
Richman, Susan D.
Quirke, Philip
Butler, Rachel
Brown, Ewan
Collinson, Fiona
Falk, Stephen
Wasan, Harpreet
Shiu, Kai-Keen
Middleton, Gary
Samuel, Leslie
Wilson, Richard H.
Brown, Louise C.
Maughan, Timothy S.
FOCUS Trial Collaboration

Open PDF

Open link

Publication date

November 2021

DOI

10.1200/JCO.21.01436

Publisher

American Society of Clinical Oncology (ASCO)

Journal

Journal of Clinical Oncology

Language

English

Abstract

SUPPORT Supported by Cancer Research UK and the National Institute for Health Research (NIHR).Peer reviewedPublisher PD

Extracted data

We use cookies to provide a better user experience.

Data Protection

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Adams, Richard A.
Fisher, David J.
Graham, Janet
Seligmann, Jenny F.
Seymour, Matthew
Kaplan, Richard
Yates, Emma
Parmar, Mahesh
Richman, Susan D.
Quirke, Philip
Butler, Rachel
Brown, Ewan
Collinson, Fiona
Falk, Stephen
Wasan, Harpreet
Shiu, Kai-Keen
Middleton, Gary
Samuel, Leslie
Wilson, Richard H.
Brown, Louise C.
Maughan, Timothy S.
FOCUS Trial Collaboration

Open PDF

Open link

Publication date

November 2021

DOI

10.1200/JCO.21.01436

Publisher

American Society of Clinical Oncology (ASCO)

Journal

Journal of Clinical Oncology

Language

English

Abstract

SUPPORT Supported by Cancer Research UK and the National Institute for Health Research (NIHR).Peer reviewedPublisher PD

Extracted data

Tebbutt, Niall C.
Wilson, Kate
Gebski, Val J.
Cummins, Michelle M.
Zannino, Diana
Van Hazel, Guy A.
Robinson, Bridget
Broad, Adam
Ganju, Vinod
Ackland, Stephen P.
Forgeson, Garry
Cunningham, David
Saunders, Mark P.
Stockler, Martin R.
Chua, Yujo
Zalcberg, John R.
Simes, R. John
Price, Timothy J.
Price, Tim
Simes, John
Coates, Alan
O'Connell, Diane
Brown, Chris
Hague, Wendy
France, Alyson
Hicks, Sian
James, Rebecca
Masson, Ruby
O'Connell, Rachel
Pike, Rhana
Shoulder, Julia

July 2010

Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monothe...

Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients with Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study

Twelves, CJ
Butts, CA
Cassidy, J
Conroy, T
Braud, F
Diaz-Rubio, E
Tabernero, JM
Schoffski, P
Figer, A
Brunet, R
Grossmann, J
Sobrero, AF
Van Cutsem, EJ

July 2005

Purpose: The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those...

Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial

Adams, Richard A.
Fisher, David J.
Graham, Janet
Seligmann, Jenny F.
Seymour, Matthew
Kaplan, Richard
Yates, Emma
Parmar, Mahesh
Richman, Susan D.
Quirke, Philip
Butler, Rachel
Brown, Ewan
Collinson, Fiona
Falk, Stephen
Wasan, Harpreet
Shiu, Kai-Keen
Middleton, Gary
Samuel, Leslie
Wilson, Richard H.
Brown, Louise C.
Maughan, Timothy S.

November 2021

Purpose: Despite extensive randomized evidence supporting the use of treatment breaks in metastati...

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Adams, RA
Fisher, DJ
Graham, J
Seligmann, JF
Seymour, M
Kaplan, R
Yates, E
Parmar, M
Richman, SD
Quirke, P
Butler, R
Brown, E
Collinson, F
Falk, S
Wasan, H
Shiu, K-K
Middleton, G
Samuel, L
Wilson, RH
Brown, LC
Maughan, TS
FOCUS4 Trial Investigators

September 2021

PURPOSE: Despite extensive randomized evidence supporting the use of treatment breaks in metastati...

Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.

Adams, R
Fisher, D
Graham, J
Seligmann, JF
Seymour, M
Kaplan, RS
Yates, E
Richman, SD
Quirke, P
Butler, R
Brown, E
Falk, S
Collinson, FJ
Wilson, RH
Brown, LC
Maughan, T

May 2021

3504 Background: There is extensive randomised evidence supporting the use of treatment breaks in ...

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3) : a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Simkens, Lieke H J
van Tinteren, Harm
May, Anne
ten Tije, Albert J
Creemers, Geert-Jan M
Loosveld, Olaf J L
de Jongh, Felix E
Erdkamp, Frans L G
Erjavec, Zoran
van der Torren, Adelheid M E
Tol, Jolien
Braun, Hans J J
Nieboer, Peter
van der Hoeven, Jacobus J M
Haasjes, Janny G
Jansen, Rob L H
Wals, Jaap
Cats, Annemieke
Derleyn, Veerle A
Honkoop, Aafke H
Mol, Linda
Punt, Cornelis J A
Koopman, Miriam

January 2015

BACKGROUND: The optimum duration of first-line treatment with chemotherapy in combination with bevac...

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Simkens, L.H.
Tinteren, H. van
May, A.
Tije, A.J. Ten
Creemers, G.J.
Loosveld, O.J.
Jongh, F.E. de
Erdkamp, F.L.
Erjavec, Z.
Torren, A.M. van der
Tol, J.
Braun, H.J.
Nieboer, P.
Hoeven, J.J.M. van der
Haasjes, J.G.
Jansen, R.L.
Wals, J.
Cats, A.
Derleyn, V.A.
Honkoop, A.H.
Mol, L.
Punt, C.J.A.
Koopman, M.

January 2015

Item does not contain fulltextBACKGROUND: The optimum duration of first-line treatment with chemothe...

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

Cassidy, J
Twelves, C
Van Cutsem, E
Hoff, P
Bajetta, E
Boyer, M
Bugat, R
Burger, U
Garin, A
Graeven, U
McKendrick, J
Maroun, J
Marshall, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schilsky, RL

April 2002

Purpose: To evaluate the safety profile of capecitabine using data from a large, well-characterized ...

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study

Van Cutsem, E
Twelves, C
Cassidy, J
Allman, D
Bajetta, E
Boyer, M
Bugat, R
Findlay, M
Frings, S
Jahn, M
McKendrick, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schmiegel, WH
Seitz, JF
Thompson, P
Vieitez, JM
Weitzel, C
Harper, P

November 2001

Purpose: To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Labor...

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer : Updated results and molecular subgroup analyses of the phase 3 CAIRO3 study

Goey, K. K.H.
Elias, S. G.
van Tinteren, H.
Laclé, M. M.
Willems, S. M.
Offerhaus, G. J.A.
de Leng, W. W.J.
Strengman, E.
ten Tije, Albert J
Creemers, Geert Jan M
van der Velden, A.
de Jongh, Felix E
Erdkamp, Frans L G
Tanis, B C
Punt, C. J A
Koopman, Miriam

January 2017

Background: The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance t...

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study

C. Twelves
C. Butts
J. Cassidy
T. Conroy
F. de Braud
E. Diaz-Rubio
J. Tabernero
P. Schoffski
A. Figer
R. Brunet
J. Grossmann
A. Sobrero
E. Van Cutsem

January 2005

PURPOSE: The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those...

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Tebbutt, Niall C.
Wilson, Kate
Forgeson, Garry
Cunningham, David
Saunders, Mark P.
Stockler, Martin R.
Chua, Yujo
Zalcberg, John R.
Simes, R. John
Price, Timothy J.
Gebski, Val J.
Cummins, Michelle M.
Zannino, Dianna
van Hazel, Guy A.
Robinson, Bridget
Broad, Adam
Ganju, Vinod
Ackland, Stephen P.

January 2010

Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monothe...

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study

Tebbutt, Niall C.
Wilson, Kate
Gebski, Val J.
Cummins, Michelle M.
Zannino, Diana
Van Hazel, Guy A.
Robinson, Bridget
Broad, Adam
Ganju, Vinod
Ackland, Stephen P.
Forgeson, Garry
Cunningham, David
Saunders, Mark P.
Stockler, Martin R.
Chua, Yujo
Zalcberg, John R.
Simes, R. John
Price, Timothy J.
Price, Tim
Simes, John
Coates, Alan
O'Connell, Diane
Brown, Chris
Hague, Wendy
France, Alyson
Hicks, Sian
James, Rebecca
Masson, Ruby
O'Connell, Rachel
Pike, Rhana
Shoulder, Julia

July 2010

Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monothe...

Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients with Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study

Twelves, CJ
Butts, CA
Cassidy, J
Conroy, T
Braud, F
Diaz-Rubio, E
Tabernero, JM
Schoffski, P
Figer, A
Brunet, R
Grossmann, J
Sobrero, AF
Van Cutsem, EJ

July 2005

Purpose: The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those...

Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial

Adams, Richard A.
Fisher, David J.
Graham, Janet
Seligmann, Jenny F.
Seymour, Matthew
Kaplan, Richard
Yates, Emma
Parmar, Mahesh
Richman, Susan D.
Quirke, Philip
Butler, Rachel
Brown, Ewan
Collinson, Fiona
Falk, Stephen
Wasan, Harpreet
Shiu, Kai-Keen
Middleton, Gary
Samuel, Leslie
Wilson, Richard H.
Brown, Louise C.
Maughan, Timothy S.

November 2021

Purpose: Despite extensive randomized evidence supporting the use of treatment breaks in metastati...

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Adams, RA
Fisher, DJ
Graham, J
Seligmann, JF
Seymour, M
Kaplan, R
Yates, E
Parmar, M
Richman, SD
Quirke, P
Butler, R
Brown, E
Collinson, F
Falk, S
Wasan, H
Shiu, K-K
Middleton, G
Samuel, L
Wilson, RH
Brown, LC
Maughan, TS
FOCUS4 Trial Investigators

September 2021

PURPOSE: Despite extensive randomized evidence supporting the use of treatment breaks in metastati...

Adams, R
Fisher, D
Graham, J
Seligmann, JF
Seymour, M
Kaplan, RS
Yates, E
Richman, SD
Quirke, P
Butler, R
Brown, E
Falk, S
Collinson, FJ
Wilson, RH
Brown, LC
Maughan, T

May 2021

3504 Background: There is extensive randomised evidence supporting the use of treatment breaks in ...

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3) : a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Simkens, Lieke H J
van Tinteren, Harm
May, Anne
ten Tije, Albert J
Creemers, Geert-Jan M
Loosveld, Olaf J L
de Jongh, Felix E
Erdkamp, Frans L G
Erjavec, Zoran
van der Torren, Adelheid M E
Tol, Jolien
Braun, Hans J J
Nieboer, Peter
van der Hoeven, Jacobus J M
Haasjes, Janny G
Jansen, Rob L H
Wals, Jaap
Cats, Annemieke
Derleyn, Veerle A
Honkoop, Aafke H
Mol, Linda
Punt, Cornelis J A
Koopman, Miriam

January 2015

BACKGROUND: The optimum duration of first-line treatment with chemotherapy in combination with bevac...

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Simkens, L.H.
Tinteren, H. van
May, A.
Tije, A.J. Ten
Creemers, G.J.
Loosveld, O.J.
Jongh, F.E. de
Erdkamp, F.L.
Erjavec, Z.
Torren, A.M. van der
Tol, J.
Braun, H.J.
Nieboer, P.
Hoeven, J.J.M. van der
Haasjes, J.G.
Jansen, R.L.
Wals, J.
Cats, A.
Derleyn, V.A.
Honkoop, A.H.
Mol, L.
Punt, C.J.A.
Koopman, M.

January 2015

Item does not contain fulltextBACKGROUND: The optimum duration of first-line treatment with chemothe...

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

Cassidy, J
Twelves, C
Van Cutsem, E
Hoff, P
Bajetta, E
Boyer, M
Bugat, R
Burger, U
Garin, A
Graeven, U
McKendrick, J
Maroun, J
Marshall, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schilsky, RL

April 2002

Purpose: To evaluate the safety profile of capecitabine using data from a large, well-characterized ...

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study

Van Cutsem, E
Twelves, C
Cassidy, J
Allman, D
Bajetta, E
Boyer, M
Bugat, R
Findlay, M
Frings, S
Jahn, M
McKendrick, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schmiegel, WH
Seitz, JF
Thompson, P
Vieitez, JM
Weitzel, C
Harper, P

November 2001

Purpose: To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Labor...

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer : Updated results and molecular subgroup analyses of the phase 3 CAIRO3 study

Goey, K. K.H.
Elias, S. G.
van Tinteren, H.
Laclé, M. M.
Willems, S. M.
Offerhaus, G. J.A.
de Leng, W. W.J.
Strengman, E.
ten Tije, Albert J
Creemers, Geert Jan M
van der Velden, A.
de Jongh, Felix E
Erdkamp, Frans L G
Tanis, B C
Punt, C. J A
Koopman, Miriam

January 2017

Background: The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance t...

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study

C. Twelves
C. Butts
J. Cassidy
T. Conroy
F. de Braud
E. Diaz-Rubio
J. Tabernero
P. Schoffski
A. Figer
R. Brunet
J. Grossmann
A. Sobrero
E. Van Cutsem

January 2005

PURPOSE: The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those...

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Tebbutt, Niall C.
Wilson, Kate
Forgeson, Garry
Cunningham, David
Saunders, Mark P.
Stockler, Martin R.
Chua, Yujo
Zalcberg, John R.
Simes, R. John
Price, Timothy J.
Gebski, Val J.
Cummins, Michelle M.
Zannino, Dianna
van Hazel, Guy A.
Robinson, Bridget
Broad, Adam
Ganju, Vinod
Ackland, Stephen P.

January 2010

Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monothe...

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study

Tebbutt, Niall C.
Wilson, Kate
Gebski, Val J.
Cummins, Michelle M.
Zannino, Diana
Van Hazel, Guy A.
Robinson, Bridget
Broad, Adam
Ganju, Vinod
Ackland, Stephen P.
Forgeson, Garry
Cunningham, David
Saunders, Mark P.
Stockler, Martin R.
Chua, Yujo
Zalcberg, John R.
Simes, R. John
Price, Timothy J.
Price, Tim
Simes, John
Coates, Alan
O'Connell, Diane
Brown, Chris
Hague, Wendy
France, Alyson
Hicks, Sian
James, Rebecca
Masson, Ruby
O'Connell, Rachel
Pike, Rhana
Shoulder, Julia

July 2010

Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monothe...

Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients with Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study

Twelves, CJ
Butts, CA
Cassidy, J
Conroy, T
Braud, F
Diaz-Rubio, E
Tabernero, JM
Schoffski, P
Figer, A
Brunet, R
Grossmann, J
Sobrero, AF
Van Cutsem, EJ

July 2005

Purpose: The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those...

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Abstract

Extracted data

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy : Results of the Randomized FOCUS4-N Trial

Abstract

Extracted data

Related items

Related items